Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fremanezumab (TEV-48125), a humanized IgG2a monoclonal antibody, potently and selectively targets the calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide implicated in the central and peripheral mechanisms of migraine. It holds promise for research into chronic migraine treatment [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Fremanezumab (TEV-48125), a humanized IgG2a monoclonal antibody, potently and selectively targets the calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide implicated in the central and peripheral mechanisms of migraine. It holds promise for research into chronic migraine treatment [1]. |
Molecular Weight | N/A |
CAS No. | 1655501-53-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fremanezumab 1655501-53-3 inhibitor inhibit